The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Squamous Non-Small Cell Lung Cancer Therapeutics-Global Market Insights and Sales Trends 2025
Synopsis
The global Squamous Non-Small Cell Lung Cancer Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Squamous Non-Small Cell Lung Cancer Therapeutics in various end use industries. The expanding demands from the Research Center, Hospital and Clinic,, are propelling Squamous Non-Small Cell Lung Cancer Therapeutics market. BMS-906024, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Buparlisib Hydrochloride segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Squamous Non-Small Cell Lung Cancer Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Squamous Non-Small Cell Lung Cancer Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Squamous Non-Small Cell Lung Cancer Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Squamous Non-Small Cell Lung Cancer Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Squamous Non-Small Cell Lung Cancer Therapeutics covered in this report include Ascenta Therapeutics, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Bayer AG, BIND Therapeutics, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company and F. Hoffmann-La Roche Ltd., etc.
The global Squamous Non-Small Cell Lung Cancer Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Ascenta Therapeutics, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Incyte Corporation
Johnson & Johnson
MacroGenics, Inc.
Novartis AG
Oncogenex Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
Global Squamous Non-Small Cell Lung Cancer Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Squamous Non-Small Cell Lung Cancer Therapeutics market, Segment by Type:
BMS-906024
Buparlisib Hydrochloride
FP-1039
Ipilimumab
JNJ-42756493
Lenvatinib
Others
Global Squamous Non-Small Cell Lung Cancer Therapeutics market, by Application
Research Center
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Squamous Non-Small Cell Lung Cancer Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Squamous Non-Small Cell Lung Cancer Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Squamous Non-Small Cell Lung Cancer Therapeutics in various end use industries. The expanding demands from the Research Center, Hospital and Clinic,, are propelling Squamous Non-Small Cell Lung Cancer Therapeutics market. BMS-906024, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Buparlisib Hydrochloride segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Squamous Non-Small Cell Lung Cancer Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Squamous Non-Small Cell Lung Cancer Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Squamous Non-Small Cell Lung Cancer Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Squamous Non-Small Cell Lung Cancer Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Squamous Non-Small Cell Lung Cancer Therapeutics covered in this report include Ascenta Therapeutics, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Bayer AG, BIND Therapeutics, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company and F. Hoffmann-La Roche Ltd., etc.
The global Squamous Non-Small Cell Lung Cancer Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Ascenta Therapeutics, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Incyte Corporation
Johnson & Johnson
MacroGenics, Inc.
Novartis AG
Oncogenex Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
Global Squamous Non-Small Cell Lung Cancer Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Squamous Non-Small Cell Lung Cancer Therapeutics market, Segment by Type:
BMS-906024
Buparlisib Hydrochloride
FP-1039
Ipilimumab
JNJ-42756493
Lenvatinib
Others
Global Squamous Non-Small Cell Lung Cancer Therapeutics market, by Application
Research Center
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Squamous Non-Small Cell Lung Cancer Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Squamous Non-Small Cell Lung Cancer Therapeutics
1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview
1.1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Product Scope
1.1.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Status and Outlook
1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2018-2029)
1.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2018-2029)
1.6.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2018-2029)
1.6.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2018-2029)
1.6.4 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2018-2029)
2 Squamous Non-Small Cell Lung Cancer Therapeutics Market by Type
2.1 Introduction
2.1.1 BMS-906024
2.1.2 Buparlisib Hydrochloride
2.1.3 FP-1039
2.1.4 Ipilimumab
2.1.5 JNJ-42756493
2.1.6 Lenvatinib
2.1.7 Others
2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Breakdown by Type (2018-2029)
3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Research Center
3.1.2 Hospital
3.1.3 Clinic
3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Breakdown by Application (2018-2029)
4 Squamous Non-Small Cell Lung Cancer Therapeutics Competition Analysis by Players
4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2022)
4.3 Date of Key Players Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
4.4 Global Top Players Squamous Non-Small Cell Lung Cancer Therapeutics Headquarters and Area Served
4.5 Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Ascenta Therapeutics, Inc.
5.1.1 Ascenta Therapeutics, Inc. Profile
5.1.2 Ascenta Therapeutics, Inc. Main Business
5.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.1.4 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Ascenta Therapeutics, Inc. Recent Developments
5.2 AstraZeneca Plc
5.2.1 AstraZeneca Plc Profile
5.2.2 AstraZeneca Plc Main Business
5.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.2.4 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 AstraZeneca Plc Recent Developments
5.3 AVEO Pharmaceuticals, Inc.
5.3.1 AVEO Pharmaceuticals, Inc. Profile
5.3.2 AVEO Pharmaceuticals, Inc. Main Business
5.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.3.4 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Bayer AG Recent Developments
5.4 Bayer AG
5.4.1 Bayer AG Profile
5.4.2 Bayer AG Main Business
5.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.4.4 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Bayer AG Recent Developments
5.5 BIND Therapeutics, Inc.
5.5.1 BIND Therapeutics, Inc. Profile
5.5.2 BIND Therapeutics, Inc. Main Business
5.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.5.4 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 BIND Therapeutics, Inc. Recent Developments
5.6 Boehringer Ingelheim GmbH
5.6.1 Boehringer Ingelheim GmbH Profile
5.6.2 Boehringer Ingelheim GmbH Main Business
5.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.6.4 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Boehringer Ingelheim GmbH Recent Developments
5.7 Bristol-Myers Squibb Company
5.7.1 Bristol-Myers Squibb Company Profile
5.7.2 Bristol-Myers Squibb Company Main Business
5.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.7.4 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Bristol-Myers Squibb Company Recent Developments
5.8 Eli Lilly and Company
5.8.1 Eli Lilly and Company Profile
5.8.2 Eli Lilly and Company Main Business
5.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.8.4 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Eli Lilly and Company Recent Developments
5.9 F. Hoffmann-La Roche Ltd.
5.9.1 F. Hoffmann-La Roche Ltd. Profile
5.9.2 F. Hoffmann-La Roche Ltd. Main Business
5.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.9.4 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 F. Hoffmann-La Roche Ltd. Recent Developments
5.10 Five Prime Therapeutics, Inc.
5.10.1 Five Prime Therapeutics, Inc. Profile
5.10.2 Five Prime Therapeutics, Inc. Main Business
5.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.10.4 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Five Prime Therapeutics, Inc. Recent Developments
5.11 Genentech, Inc.
5.11.1 Genentech, Inc. Profile
5.11.2 Genentech, Inc. Main Business
5.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.11.4 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Genentech, Inc. Recent Developments
5.12 Incyte Corporation
5.12.1 Incyte Corporation Profile
5.12.2 Incyte Corporation Main Business
5.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.12.4 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 Incyte Corporation Recent Developments
5.13 Johnson & Johnson
5.13.1 Johnson & Johnson Profile
5.13.2 Johnson & Johnson Main Business
5.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.13.4 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.13.5 Johnson & Johnson Recent Developments
5.14 MacroGenics, Inc.
5.14.1 MacroGenics, Inc. Profile
5.14.2 MacroGenics, Inc. Main Business
5.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.14.4 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.14.5 MacroGenics, Inc. Recent Developments
5.15 Novartis AG
5.15.1 Novartis AG Profile
5.15.2 Novartis AG Main Business
5.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.15.4 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.15.5 Novartis AG Recent Developments
5.16 Oncogenex Pharmaceuticals, Inc.
5.16.1 Oncogenex Pharmaceuticals, Inc. Profile
5.16.2 Oncogenex Pharmaceuticals, Inc. Main Business
5.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.16.4 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.16.5 Oncogenex Pharmaceuticals, Inc. Recent Developments
5.17 PsiOxus Therapeutics Limited
5.17.1 PsiOxus Therapeutics Limited Profile
5.17.2 PsiOxus Therapeutics Limited Main Business
5.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.17.4 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.17.5 PsiOxus Therapeutics Limited Recent Developments
6 North America
6.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Squamous Non-Small Cell Lung Cancer Therapeutics Market Dynamics
11.1 Squamous Non-Small Cell Lung Cancer Therapeutics Industry Trends
11.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers
11.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
11.4 Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
